The role of tranexamic acid in decreasing blood loss in developmental dysplasia of the hip surgery: a prospective cohort study

Document Type : RESEARCH PAPER

Authors

1 Department of Surgery, College of Medicine, University of Duhok

2 Department of orthopedics, Azadi teaching hospital, Candidate of Kurdistan Higher Council for Medical Specialization

10.22038/abjs.2026.92970.4209

Abstract

Objectives: To compare two groups of patients undergoing hip surgery for DDH (those who received TXA pre- and per-operatively with those who did not) with respect to the amount and percentage of blood loss and the need for blood transfusion in a prospective cohort study.

Methods: The study was a comparative, prospective cohort study. The participants were children with DDH who required surgical treatment, including bone (pelvic and femoral) osteotomies. They were divided into two groups: Group 1 consisted of patients who didn’t receive TXA (control group), while Group 2 consisted of those who received it (experimental group).

Results: One hundred and two cases (51 in each group) were included in the current study. Group 1 did not differ statistically from Group 2 in mean age, sex, grade of DDH, mean number of osteotomies, mean blood loss, mean percentage of blood loss, or mean odds of blood transfusion. The amount and rate of blood loss showed a weak positive correlation with patient age and sex, but this association was not statistically significant. Their correlations with DDH grade, number of osteotomies, and odds of blood transfusion were also positive, but statistically significant.

Conclusion: There was no statistically significant difference between those who didn’t receive and those who received tranexamic acid in reducing the amount and percentage of blood loss, and odds of blood transfusion in children who underwent DDH surgery with bone osteotomies.

Keywords

Main Subjects



Articles in Press, Accepted Manuscript
Available Online from 24 May 2026
  • Receive Date: 22 November 2025
  • Revise Date: 10 May 2026
  • Accept Date: 17 May 2026